Clinical Trial Update: Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial at Fudan University evaluating pemetrexed and carboplatin with or without anlotinib for osimertinib-resistant non-squamous non-small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)
• CARBOPLATIN (Carboplatin)
• Pemetrexed (Alimta) (pemetrexed)

Snippet

Sponsor: Fudan University | Conditions: NSCLC Stage IV | Phase 2 | Status: RECRUITING